SNMMI/EANM practice guideline vs. ETA Consensus Statement: differences and similarities in approaching differentiated thyroid cancer management—the EANM perspective Petra Petranović OvčaričekMichael C. KreisslLuca Giovanella Editorial 10 August 2022 Pages: 3959 - 3963
[64Cu]Cu-ATSM: an emerging theranostic agent for cancer and neuroinflammation Fang XieWeijun Wei Editorial 03 August 2022 Pages: 3964 - 3972
PSMA-targeted theranostics of solid tumors: applications beyond prostate cancers Shuxian AnGang HuangWeijun Wei Editorial 02 August 2022 Pages: 3973 - 3976
The era of prostate-specific membrane antigen (PSMA)–based theranostics for hepatocellular carcinoma is upcoming: are we ready for it? Luca FilippiArthur J. BraatOrazio Schillaci Letter to the Editor 10 August 2022 Pages: 3977 - 3978
Shining new light on lung cancer diagnosis using a pafolacianine molecular tracer T. KramerP. I. BontaJ. T. Annema Letter to the Editor 10 August 2022 Pages: 3979 - 3980
Repair of α-particle-induced DNA damage in peripheral blood mononuclear cells after internal ex vivo irradiation with 223Ra Lukas GöringSarah SchumannUta Eberlein Original Article Open access 27 June 2022 Pages: 3981 - 3988
Predicting response of micrometastases with MIRDcell V3: proof of principle with 225Ac-DOTA encapsulating liposomes that produce different activity distributions in tumor spheroids Sumudu KatugampolaJianchao WangRoger W. Howell Original Article 08 July 2022 Pages: 3989 - 3999
PET imaging of hepatocellular carcinoma by targeting tumor-associated endothelium using [68Ga]Ga-PSMA-617 Qiaomiao LuYu LongXiaoli Lan Original Article 28 June 2022 Pages: 4000 - 4013
The optimal 18F-fluoromisonidazole PET threshold to define tumor hypoxia in preclinical squamous cell carcinomas using pO2 electron paramagnetic resonance imaging as reference truth Inna GertsenshteynBoris EpelChin-Tu Chen Original Article 06 July 2022 Pages: 4014 - 4024
Preclinical evaluation and pilot clinical study of [18F]AlF-NOTA-FAPI-04 for PET imaging of rheumatoid arthritis Luna GeZheng FuLin Wang Original Article 18 June 2022 Pages: 4025 - 4036
A first-in-human study of [68Ga]Ga-CDI: a positron emitting radiopharmaceutical for imaging tumour cell death Ivan Ho ShonThomas HennessyPhilip J. Hogg Original Article Open access 02 July 2022 Pages: 4037 - 4047
Direct inference of Patlak parametric images in whole-body PET/CT imaging using convolutional neural networks Neda ZakerKamal HaddadHabib Zaidi Original Article Open access 18 June 2022 Pages: 4048 - 4063
Application of machine learning to pretherapeutically estimate dosimetry in men with advanced prostate cancer treated with 177Lu-PSMA I&T therapy Song XueAndrei GafitaKuangyu Shi Short Communication Open access 30 June 2022 Pages: 4064 - 4072
In vivo detection of hydrogen sulfide in the brain of live mouse: application in neuroinflammation models Bora NamWoonghee LeeJeongsoo Yoo Original Article 10 June 2022 Pages: 4073 - 4087
PET/CT imaging of CSF1R in a mouse model of tuberculosis Catherine A. FossAlvaro A. OrdonezAndrew G. Horti Original Article 17 June 2022 Pages: 4088 - 4096
A comparison of advanced semi-quantitative amyloid PET analysis methods Enrico PeiraDavide PoggialiDiego Cecchin Original Article Open access 02 June 2022 Pages: 4097 - 4108
Improving the imaging diagnostic strategy for pulmonary artery masses based on 18F-FDG PET/CT integrated with CTPA Cheng HongPeng HouXin-lu Wang Original Article 23 June 2022 Pages: 4109 - 4121
Reproducibility of quantitative coronary calcium scoring from PET/CT attenuation maps: comparison to ECG-gated CT scans Konrad PieszkoAakash D. ShanbhagPiotr J. Slomka Original Article 25 June 2022 Pages: 4122 - 4132
CXCR4-targeted theranostics in oncology Andreas K. BuckSebastian E. SerflingRudolf A. Werner Review Article Open access 08 June 2022 Pages: 4133 - 4144
Evaluation of pediatric malignancies using total-body PET/CT with half-dose [18F]-FDG Wanqi ChenLei LiuYingying Hu Original Article 05 July 2022 Pages: 4145 - 4155
Visualizing γδ T cells by very late antigen-4-targeted positron emission tomography Yu LongXiaoying LvXiaoli Lan Original Article 06 July 2022 Pages: 4156 - 4170
Novel recombinant human thyroid-stimulating hormone in aiding postoperative assessment of patients with differentiated thyroid cancer—phase I/II study Yan-Song LinHui YangBao-Xia He Original Article 04 July 2022 Pages: 4171 - 4181
Correlation of somatostatin receptor PET/CT imaging features and immunohistochemistry in neuroendocrine tumors of the lung: a retrospective observational study Vittoria RufiniMargherita LorussoGuido Rindi Original Article Open access 08 June 2022 Pages: 4182 - 4193
Targeted detection of cancer cells during biopsy allows real-time diagnosis of pulmonary nodules Gregory T. KennedyFeredun S. AzariSunil Singhal Original Article Open access 05 July 2022 Pages: 4194 - 4204
Diagnostic performance of [18F]-FDG PET/MR in evaluating colorectal cancer: a systematic review and meta-analysis Seyed Ali MirshahvaladRicarda HinzpeterPatrick Veit-Haibach Review Article 16 June 2022 Pages: 4205 - 4217
A prospective head-to-head comparison of 68 Ga-NOTA-3P-TATE-RGD and 68 Ga-DOTATATE in patients with gastroenteropancreatic neuroendocrine tumours Yuanyuan JiangQingxing LiuZhaohui Zhu Original Article 03 June 2022 Pages: 4218 - 4227
Gallium-68-labeled fibroblast activation protein inhibitor PET in gastrointestinal cancer: insights into diagnosis and management Chunxia QinYangmeihui SongXiaoli Lan Original Article 03 June 2022 Pages: 4228 - 4240
The role of 18F-FDG PET/CT in predicting the pathological response to neoadjuvant PD-1 blockade in combination with chemotherapy for resectable esophageal squamous cell carcinoma Xiaoyan WangWeixiong YangChao Cheng Original Article 23 June 2022 Pages: 4241 - 4251
Comparing the clinical performance and cost efficacy of [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 in the diagnosis of recurrent prostate cancer: a Markov chain decision analysis Ian AlbertsClemens MingelsAli Afshar-Oromieh Original Article Open access 13 November 2021 Pages: 4252 - 4261
Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [177Lu]Lu-PSMA I&T during long-term follow-up Philipp E. HartrampfAnna Katharina SeitzRudolf A. Werner Original Article Open access 02 June 2022 Pages: 4262 - 4270
Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria Andrei GafitaIsabel RauscherMatthias R. Benz Original Article 29 June 2022 Pages: 4271 - 4281
Increased TSPO PET signal after radiochemotherapy in IDH-wildtype glioma—indicator for treatment-induced immune activation? Stefanie QuachAdrien HolzgreveNathalie L. Albert Image of the Month Open access 25 May 2022 Pages: 4282 - 4283
Primary biphasic synovial sarcoma of the liver with multiple bone metastases detected by PET/CT Miao LiuHua ShangPeng Xie Image of the Month 11 June 2022 Pages: 4284 - 4285
Complementary value of metabolic and tau PET imaging in the diagnosis of corticobasal degeneration Menglin LiangChenhao JiaRuixue Cui Image of the Month 20 June 2022 Pages: 4286 - 4288
Correction to: Correlation of somatostatin receptor PET/CT imaging features and immunohistochemistry in neuroendocrine tumors of the lung: a retrospective observational study Vittoria RufiniMargherita LorussoGuido Rindi Correction Open access 14 June 2022 Pages: 4289 - 4289
Correction to: Visualizing γδ T cells by very late antigen-4-targeted positron emission tomography Yu LongXiaoying LvXiaoli Lan Correction 18 July 2022 Pages: 4290 - 4291